Evommune
EVMNEVMN · Stock Price
Historical price data
Overview
Evommune is a clinical-stage biotech developing oral therapies targeting mast cells and sensory neurons to address the root causes of chronic inflammatory diseases like atopic dermatitis and chronic spontaneous urticaria. The company has advanced two lead programs, EVO756 and EVO301, into Phase 2 trials, supported by a recent $125 million private placement. Its strategy focuses on achieving disease-modifying effects with convenient oral dosing, aiming to capture significant share in multi-billion dollar immunology markets with high unmet need.
Technology Platform
A proprietary platform focused on the selective modulation of mast cells and sensory neurons via targets like MRGPRX2 and IL-18 to address the root causes of chronic inflammation and pruritus.
Pipeline
6| Drug | Indication | Stage | Watch |
|---|---|---|---|
| EVO756 + EVO756 + EVO756 + Placebo control | Atoptic Dermatitis | Phase 2 | |
| EVO756 + EVO756 + EVO756 + Placebo control | Chronic Spontaneous Urticaria | Phase 2 | |
| EVO301 + Placebo | Atopic Dermatitis (AD) | Phase 2 | |
| Oral EVO756 | Chronic Inducible Urticaria | Phase 2 | |
| EVO101 | Atopic Dermatitis Eczema | Phase 2 |
Funding History
1Opportunities
Risk Factors
Competitive Landscape
Evommune faces competition from large-cap biopharma with entrenched biologics (e.g., Dupixent in AD, Xolair in CSU). Its edge lies in first-in-class oral mechanisms (MRGPRX2, IL-18), targeting the mast cell-itch axis directly, and an experienced team capable of efficient execution through key clinical milestones.